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Objectives: Some patients and oncologists choose to treat localized esophageal can-
cer with definitive chemotherapy and radiation therapy rather than surgery. A sub-
set of these patients have local relapse without distant metastases and therefore have
no other curative intent treatment option but salvage esophagectomy.
Methods: We reviewed our experience with salvage esophagectomy from 1987 to
2000 at M.D. Anderson Cancer Center (n = 13, salvage after chemotherapy and
radiotherapy group) and compared the data with those of patients receiving
esophagectomy in a planned fashion 4 to 6 weeks after preoperative chemotherapy
and radiation therapy (n = 99, preoperative chemotherapy and radiotherapy group).
Results: Increases in morbidity were seen after resection in the salvage after
chemotherapy and radiotherapy group relative to the preoperative chemotherapy
and radiotherapy group: mechanical ventilation (9.0 days vs 3.3 days, P = .08),
intensive care unit stay (11.2 days vs 5.1 days, P = .07), hospital stay (29.4 days vs
18.4 days, P = .03), and anastomotic leak rates (5/13 [39%] vs 7/99 [7%], P = .005).
Operative mortality (within 30 days) also tended to be increased statistically non-
significantly (2/13 [15%] vs 6/99 [6%], P = .2). Salvage esophagectomy resulted in
long-term survival (25% 5-year survival) in a subset of patients. Improved survival
after salvage esophagectomy was associated with early pathologic stage (T1 N0, T2
N0), prolonged time to relapse, and R0 surgical resection.
Conclusion: Patients who undergo salvage esophagectomy for relapse of tumor after
definitive chemoradiation therapy have increased morbidity, mortality, and hospital
use relative to patients undergoing planned esophagectomy after preoperative
chemoradiation. Nevertheless, long-term survival can be achieved in this group, and
such treatment should be considered for carefully selected patients at an experi-
enced center.
The optimal therapy for locoregionally advanced esophageal cancerhas not yet been determined. Some groups advocate surgical resec-tion for all patients, either alone or in combination with preoperativechemotherapy or chemoradiation therapy.1-4 Other oncologists advo-cate a primarily nonsurgical approach with definitive chemoradia-tion therapy alone.5-9 Although long-term survival can be achieved
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through this nonoperative strategy, locoregional failure is
still a major problem, with 40% to 60% of patients having
recurrent locoregional disease.5,6 We have therefore been
faced with a subset of patients referred to our institution
who have had locoregional failure occur after definitive
chemoradiation therapy at an outside institution.
Unfortunately, many of these patients are not eligible for
salvage esophagectomy because of metastases found during
restaging or physiologic deterioration that makes surgical
risk prohibitive. Additionally, many of these patients are at
increased risk for esophagectomy because they have been
treated with higher doses of radiation and have completed
radiation treatment many months before. Despite these
increased risks, we have undertaken salvage esophagec-
tomy for a subset of these patients who are physiologically
fit for operation and have no evidence of distant metastases.
In an attempt to determine the outcome of salvage
esophagectomy, we conducted a retrospective review of all
patients undergoing esophageal resection (n = 780) between
1987 and 2000 at our institution and selected all patients
undergoing salvage esophagectomy (n = 13) for primary
relapsed tumors after failed definitive chemoradiation ther-
apy. This group was compared with a control group of
patients (n = 99) who during the same period underwent
esophageal resection as a planned procedure 4 to 6 weeks
after preoperative chemoradiation therapy.
Patients and Methods
We selected the records of all patients who underwent esophageal
resection (n = 780) between August 1987 and February 2000 at M.D.
Anderson Cancer Center and reviewed the cases of patients (n = 13)
who underwent salvage esophageal resection for recurrent esophageal
tumors after definitive chemotherapy and radiation therapy. Most of
these patients were treated initially with chemotherapy and radiation
therapy at an outside institution and came to M.D. Anderson Cancer
Center for evaluation after relapse of the primary tumor. For compar-
ison, we reviewed a group of patients (n = 99) treated with planned
esophageal resection immediately (4 to 6 weeks) after preoperative
chemotherapy and radiation therapy at M.D. Anderson Cancer Center
during the same period. Hospital records were reviewed for age, sex,
weight, height, American Society of Anesthesiology risk classifica-
tion, preoperative medical history, pulmonary function test perfor-
mance, tumor location and histologic class, and results of preoperative
laboratory and radiographic studies. All medical charts were reviewed
for details regarding definitive or adjuvant chemotherapy and radia-
tion therapy, including radiation dose and chemotherapy drug type.
Outside hospital records from patients initially treated with definitive
chemotherapy and radiation therapy were reviewed as appropriate for
details regarding treatment. Data collected included the dates of treat-
ment, time to tumor relapse, operative time, estimated blood loss,
transfusion requirements, and technical surgical details. Perioperative
pathology reports were reviewed to determine pathologic stage and
surgical resection margins.
Short-term outcome was evaluated by reviewing duration of
ventilator dependence, days spent in the intensive care unit, days
spent in the hospital, anastomotic leak rate, and death before dis-
charge (30-day mortality). Long-term outcomes, encompassing
overall survival and recurrence rates (local and distant), were
obtained from hospital records and the M.D. Anderson Cancer
Center tumor registry. Overall survival was calculated from the
day of operation until the last known date of follow-up.
Statistical analysis was performed in association with our
departmental biostatisticians (M.B.M. and A.M.C.). Statistical
analysis included the Student t test, the Pearson χ2 test, and the
Fisher exact test as appropriate. The survival functions were esti-
mated with the Kaplan-Meier method estimator, and log-rank tests
were used to compare the survival distributions. Univariable and
multivariable analyses for survival in the salvage after chemother-
apy and radiotherapy group was performed on the 11 patients who
survived the perioperative period. Multivariable analysis was per-
formed by Cox regression and included all the variables that were
statistically significant or clinically relevant in the univariable
analyses. Software used included Microsoft Excel (Microsoft
Corporation, Redmond, Wash), Graph Pad Prism (GraphPad
Software, Inc, San Diego, Calif), and SPSS (SPSS Inc, Chicago,
Ill) statistical software.
Results
Characteristics of Patients
Thirteen patients underwent esophageal resection as a sal-
vage procedure for recurrent esophageal tumors after failed
TABLE 1. Demographic factors
Salvage after Preoperative
chemotherapy and chemotherapy and
radiotherapy group radiotherapy group
(n = 13) (n = 99) P value
Sex (No.)
Male 9 (69%) 83 (84%) .24
Female 4 (31%) 16 (16%)
Age (y)
Median 65 .05
Range 45-83 61 (39-84)
Histologic type (No.)
Adenocarcinoma 6 (46%) 74 (75%) .05
Squamous cell 7 (54%) 22 (22%)
Other 0 3 (3%)
Location (No.)
Cervical 1 (8%) 0 (0%) .00002
Upper 3 (23%) 1 (1%)
Middle 3 (23%) 19 (19%)
Lower 6 (46%) 79 (80%)
Pathologic stage (No.)
Stage 0 0 (0%) 21 (21%) .55
Stage I 2 (15%) 16 (16%)
Stage IA 5 (38%) 21 (21%)
Stage IB 2 (15%) 15 (15%)
Stage III 3 (23%) 16 (16%)
Stage IVA 1 (8%) 7 (7%)
Stage IVB 0 (0%) 3 (3%)
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definitive chemotherapy and radiation therapy (salvage
after chemotherapy and radiotherapy group) between
August 1987 and February 2000 at M.D. Anderson Cancer
Center. Most of these 13 patients were initially treated at an
outside hospital with definitive chemotherapy and radiation
therapy and were seen at M.D. Anderson Cancer Center
after relapse of the primary tumor. Only patients who had
recurrence in the same location as the original tumor were
included. A control group of 99 patients who underwent
esophageal resection as a planned procedure immediately
(4-6 weeks) after preoperative chemotherapy and radiation
therapy were used as a comparison group.
The two groups (salvage after chemotherapy and radio-
therapy group and preoperative chemotherapy and radio-
therapy group) were similar in sex distribution and
pathologic stage (Table 1). Their preoperative American
Society of Anesthesiology scores, weight loss, pulmonary
function tests and medical comorbidities were also similar
(data not shown). Patients in the salvage after chemotherapy
and radiotherapy group tended to have a higher proportion
of squamous cell carcinoma and cervical or upper location
(4/13 [31%] vs 1/99 [1%]) than those in the preoperative
chemotherapy and radiotherapy group.
The average time to relapse for the salvage after
chemotherapy and radiotherapy group was 18.1 months
(range 4.1-55.9 months) after completion of definitive
chemoradiation therapy. Patients who had relapse after
definitive chemoradiation therapy were screened for
metastatic disease by bone scan, computed tomography
(CT) of the brain, and CT of the chest and abdomen. Only
patients who did not show signs of metastatic disease and
were deemed physiologically fit were evaluated for resec-
tion. The preoperative chemotherapy and radiotherapy
group underwent resection immediately (4-6 weeks) after
preoperative chemoradiation therapy only if repeated CT of
the chest and abdomen showed no evidence of metastatic
disease. The average dose of radiation delivered to the
esophagus in the salvage after chemotherapy and radiother-
apy group was 56.7 Gy (range 30.0-90.0 Gy), as opposed to
41.4 Gy (range 30.0-60.0 Gy) in the preoperative
chemotherapy and radiotherapy group; this difference was
statistically significant (P = .002). Both groups received
regimens composed predominantly of 5-fluorouracil and
cisplatin concomitantly with radiation therapy. A minority
of patients (n = 38) in the preoperative chemotherapy and
radiotherapy group also received paclitaxel, cisplatin, and
5-fluorouracil before chemoradiation therapy.
Perioperative Factors
The salvage after chemotherapy and radiotherapy group
(Table 2) tended to have an increased number of cervical anas-
tomoses, reflecting a higher proportion of transhiatal (cervical
anastomosis) and three-field esophagectomies (transthoracic
with cervical anastomosis) rather than Ivor Lewis esophagec-
tomies (transthoracic with chest anastomosis). Anastomotic
techniques in the groups were similar, with neck anastomoses
being performed with a single layer interrupted suture tech-
nique and chest anastomoses being performed with a 2-layer
interrupted suture or stapled technique. The operative time,
blood loss, and units of transfused packed red blood cells were
increased in the salvage esophagectomy group, which may
reflect increased complexity or difficulty of resecting the
relapsed tumors (Table 2).
The immediate postoperative courses of the groups also
differed. Patients undergoing salvage esophagectomy had
increases in the durations of ventilator dependence, intensive
care unit stays, and overall hospital stays (Table 2).
Additionally, the anastomotic leak rate was significantly
increased in the salvage esophagectomy group. Perioperative
(30-day) mortality also showed a tendency to be increased
after salvage esophagectomy.
Further detailed review of the 13 patients who underwent
salvage esophagectomy revealed that adverse events were
noted in 77% (10/13). Sixty-two percent (8/13) of the
patients had some pulmonary complication, with the most
TABLE 2. Perioperative factors
Salvage after Preoperative
chemotherapy and chemotherapy and
radiotherapy group radiotherapy group
(n = 13) (n = 99) P value
Location of anastomosis (No.)
Cervical
Transhiatal 2 (15%) 16 (16%) .13*
Transthoracic three-field 6 (46%) 21 (21%)
Total 8 (61%) 47 (37%)
Thoracic
Transthoracic Ivor-Lewis 5 (38%) 58 (59%)
Transabdominal 0 4 (4%)
Total 5 (38%) 62 (63%)
Operative factors
Operative time (min) 542 ± 172 429 ± 141 .006
Blood loss (mL) 1212 ± 832 843 ± 527 .07
Packed red blood 1.9 ± 2.5 0.9 ± 1.4 .09
cells (U)
Hospital factors
Mechanical 9.0 ± 13.3 3.3 ± 8.1 .08
ventilation (d)
Intensive care unit 11.2 ± 13.3 5.1 ± 9.4 .06
stay (d)
Hospital stay (d) 29.4 ± 22.4 18.4 ± 18.3 .03
Anastomotic leak (No.) 5 (38%) 7 (7%) .005
Operational mortality (30 d) 2 (15%) 6 (6%) .2
Noncategorical data expressed as mean ± SD.
*Cervical versus thoracic anastomosis.
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common being pneumonia (5 patients) or ventilatory sup-
port exceeding 48 hours (4 patients). Two patients (15%)
required tracheostomies for respiratory insufficiency and
long-term pulmonary care. Infections were the second most
common complication, occurring in 31% (4/13), and were
primarily wound related. Other complications included
renal failure (n = 1), gastric outlet obstruction (n = 1), and
ischemic conduit (n = 1). No difference was noted in the
leak rates with thoracic or cervical anastomoses in the sal-
vage after chemotherapy and radiotherapy group (thoracic
anastomosis 2/5 [40%] vs cervical anastomosis 3/8 [38%]).
Neither patient who died during the perioperative period
had a thoracic anastomosis, although 1 patient with a cervi-
cal anastomosis died because of a leak from the lesser cur-
vature into the thoracic cavity. Both patients who died
during the perioperative period (n = 2) had relapse occur
longer than 50 months after definitive chemoradiation ther-
apy, whereas all surviving patients (n = 11) had relapse
occur 24 months or less after chemoradiation therapy (P =
.01). One perioperative death was due to adult respiratory
distress syndrome and multiorgan failure, whereas the other
was due to a leak on the lesser curvature with subsequent
sepsis. No relationship was found between salvage
esophagectomy morbidity, leak rate, or length of hospital-
Figure 1. Overall survival of patients undergoing esophagectomy
after definitive chemoradiation therapy (salvage after chemother-
apy and radiotherapy, n = 13) or planned preoperative chemoradi-
ation therapy (preoperative chemotherapy and radiotherapy, n =
99). C/RT, Chemotherapy and radiotherapy.
Figure 2. Long-term survival of patients after salvage esophagec-
tomy (n = 11) according to pathologic stage (excluding periopera-
tive deaths, n = 2).
Figure 3. Long-term survival of patients after salvage esophagec-
tomy (n = 11) according to R0 resection status (excluding periop-
erative deaths, n = 2).
Figure 4. Long-term survival of patients after salvage esophagec-
tomy (n = 11) according to disease free-interval (DFI) longer than
12 months (excluding perioperative deaths, n = 2).
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ization and dose of radiation, time to relapse, location of
anastomosis, type of operative procedure, or other preoper-
ative risk factors.
Long-Term Outcome
The pathologic staging of disease in the 13 patients under-
going salvage esophagectomy was not significantly different
from that of those undergoing esophagectomy after preoper-
ative chemotherapy and radiotherapy (Table 1). Despite dif-
ferences in operative mortality and morbidity, long-term
survivals were similar (Figure 1). Salvage esophagectomy
was associated with long-term survival (5-year 25%) in a
subset of patients, with 4 patients living longer than 2 years
after the operation and 2 patients still alive without evidence
of disease 5.7 years and 12.2 years after the salvage opera-
tion. In an attempt to determine factors associated with long-
term survival after salvage esophagectomy, the 11 patients
who survived the perioperative period were evaluated for
various factors. Univariate analysis revealed that early (T1
N0, T2 N0) stage, R0 resection, and prolonged disease-free
interval (or time to relapse) were associated with increased
survival (Figures 2, 3, and 4). Multivariable analysis
revealed that the most significant factor appeared to be early
pathologic stage (hazard ratio = 6.045, P = .127), although
this was not statistically significant because of the low num-
ber of patients in the analysis and the overlap between early
stage and R0 resection (Table 3).
With a median follow-up of 27 months, 3 of 11 of the
patients in the salvage esophagectomy group who survived
the operation demonstrated locoregional recurrences (27%).
Two other patients (18%) had distant recurrences (bone and
liver). Four patients (36%) showed no evidence of tumor
recurrence after salvage esophagectomy and survived for a
prolonged period with excellent swallowing function,
whereas 2 patients (18%) showed no evidence of recurrence
but died within 6 months after the operation, possibly of
tumor relapse. Recurrence data were not applicable in 2
cases because the patients died before discharge as a result
of operative complications rather than tumor recurrence.
Discussion
The optimal treatment strategy for locoregionally advanced
esophageal cancer has not yet been determined.
Esophagectomy either alone or in combination with
chemotherapy and radiation therapy is associated with long-
term survivals of only 15% to 35%.1-4 Additionally, many
of these patients have significant weight loss and associated
comorbidities and are at high risk for perioperative morbid-
ity and mortality after an extensive surgical procedure such
as esophagectomy.10 Because of these poor outcomes with
surgery, alternative treatment strategies have been proposed
by some oncologists to treat locoregionally advanced
esophageal cancer with definitive chemoradiation therapy
and no surgery.5-7,9 These strategies, especially for squa-
mous cell cancer, can result in long-term survivals of 10%
to 30% when 5-fluorouracil and cisplatin or mitomycin are
combined with radiation therapy.6,11,12 Unfortunately,
locoregional control is often quite poor with definitive
chemoradiation therapy, and 40% to 60% of the patients
have persistent or relapsed tumor at the primary site within
1 year.5,6 Because of this we have been faced with a num-
ber of patients referred to us from outside institutions who
have been treated with definitive chemoradiation therapy
and have locoregional relapse, and there are few other cura-
tive intent treatment options except surgery. Because of the
potentially increased risks associated with the higher doses
of radiation received and the prolonged time from the com-
pletion of radiation therapy, many surgeons have been
reluctant to operate on this group. This study therefore eval-
uated our experience with salvage esophagectomy after
definitive chemoradiation therapy and compared it with a
control group of patients who underwent esophagectomy as
a planned procedure 4 to 6 weeks after completion of
chemoradiation therapy. Although the control group was
not a perfect comparison because of demographic differ-
ences in tumor and patient factors (Table 1), it still provided
a baseline to assess the feasibility of salvage esophagec-
tomy after failed definitive chemoradiation.
The number of patients (n = 13) undergoing salvage
esophagectomy during this period was relatively small in
light of the large number of esophagectomies performed at
our institution (n = 780). This may have been due in part to
the fact that many patients who had locoregional failure
after definitive chemoradiation therapy also had distant fail-
ure precluding surgical resection for cure. Additionally, our
departmental protocols have involved operative approaches
with or without chemotherapy or radiation therapy, and cur-
rently our approach for resectable esophageal cancer
involves surgical resection in combination with preopera-
tive chemoradiation therapy. We have reserved definitive
chemoradiation therapy without surgery for patients who
are not physiologically fit to undergo an operation or have
TABLE 3. Multivariable analysis of salvage esophagectomy
long-term survival
95% Confidence
Factor Hazard ratio interval P value
Relapse, <12 mo vs ≥12 mo 1.439 0.250-8.270 .684
Resection, R1 vs R0 2.611 0.375-18.204 .333
Stage, advanced stage 6.045 0.599-60.993 .127
(T3, T4, or N1) vs
early stage
(T1 N0, T2 NO)
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upper or cervical esophageal tumors, where a laryngectomy
might be required.13,14 This treatment algorithm may also
explain the preponderance of cervical and upper esophageal
tumors and squamous cell cancers in the salvage after
chemotherapy and radiotherapy group (Table 1), because
most of the patients treated initially with definitive
chemoradiation therapy have these characteristics. In fact, 3
of the 13 patients undergoing salvage esophagectomy also
underwent simultaneous laryngectomy because of the prox-
imal esophageal tumor location.
We noted a significant increase in perioperative morbid-
ity and hospital use after salvage esophagectomy (Table 2),
which may have been due in part to the locations of the
tumors and to the need for more extensive surgery and con-
comitant procedures such as laryngectomy.13,14
Additionally, many of the patients in the salvage after
chemotherapy and radiotherapy group were operated on in
the beginning of the study period (1980s), when periopera-
tive morbidity rates were higher than for those in the pre-
operative chemotherapy and radiotherapy group, who
underwent surgery predominantly at the end of the study
period (1990s).15 Other factors that may have contributed to
the increased morbidity and hospital use include the
increased difficulty of operating many months after the
completion of radiation therapy and the higher doses of
radiation therapy delivered with definitive chemoradiation
therapy, which has been associated with increased morbid-
ity and leak rates in preoperative radiation trials.16-18 In
fact, a recent randomized intergroup definitive chemoradia-
tion therapy trial was terminated early because of increased
toxicity and lower long-term survival in the higher dose
chemoradiation therapy arm (64.8 Gy vs 50.4 Gy).19 It is
therefore important that oncologists who choose to treat
patients with definitive chemoradiation therapy do not use
higher doses of radiation, because these higher doses do not
improve survival and would presumably also increase the
risks of salvage esophagectomy if needed. Our study tried
to correlate dose of radiation with morbidity but was not
able to see a clear correlation because of the small sample
size. In fact, several patients who received more than 60 Gy
of radiation still tolerated salvage esophagectomy without
significant morbidity. Additionally, those patients who
underwent an Ivor-Lewis esophagectomy with a thoracic
anastomosis did not appear to be at increased risk of death
from a thoracic leak, because all 5 of these patients sur-
vived. The only factor found to be associated with periop-
erative mortality was the length of time to relapse. Both
patients who had relapse more than 50 months after defini-
tive chemoradiation therapy died in the perioperative
period, compared with none of those who had relapse 26
months or less after such treatment (n = 11). This may have
been due to the increased amount of fibrosis seen with time
or to late esophageal changes after definitive chemoradia-
tion therapy.20 The leak rates of cervical anastomoses tend
to be higher than those of thoracic anastomoses (10%-15%
vs 2%), which may partly explain our high leak rate in the
salvage after chemotherapy and radiotherapy group (38%)
but does not explain all of it.21 In an attempt to reduce the
leak rates with salvage esophagectomy, we are currently
evaluating the benefit of using alternative vascularized con-
duits, such as colonic or free jejunal interpositions, that
have not been within the radiation field and have been asso-
ciated with low leak rates at our institution and others in
high-risk situations.22 Although there was not a significant
increase in operative mortality, it is important to recognize
that this study was performed in a high-volume esophageal
referral center (M.D. Anderson Cancer Center) with experi-
ence with high-risk esophagectomies. Perioperative mor-
bidity and mortality might have been significantly increased
in a low-volume esophageal hospital.10,23
Despite the increased morbidity and hospital use noted
with salvage esophagectomies, most of the patients sur-
vived and were discharged home able to tolerate an oral
diet. Furthermore, these patients had few other curative
intent therapeutic options, because they had already
received maximal amounts of radiation and additional
chemotherapy would not have been likely to control the
recurrent locoregional disease. Although symptoms could
have been palliated with a stent placement, this approach
would not have been curative, and other treatments (such as
photodynamic therapy and brachytherapy) remain
unproven.24-27 Most institutions that have adopted a defini-
tive chemoradiation therapy approach to esophageal cancer
include patients who have undergone salvage with
esophageal resection, and this selective approach may be
necessary to achieve long-term survival for some
patients.6,9,12 In an attempt to identify the subset of patients
that benefitted from salvage esophagectomy, we reviewed
multiple factors univariately and found that long-term sur-
vival was associated with early pathologic stage, complete
(R0) resection, and prolonged period to relapse (>12
months). Although multivariable analysis could not clearly
distinguish the most significant factor because of the small
patient numbers and overlap between the factors, early
pathologic stage that allowed R0 resection was associated
with an 86-month median survival and with long-term sur-
vival for 60% of patients. In fact, no patient with pathologic
T3, T4, or N1 disease survived longer than 7 months. This
observation suggests that salvage esophagectomy should be
reserved for these patients with early-stage disease, because
such treatment of more advanced tumors seldom results in
long-term cure. Unfortunately, it is difficult with current
endoscopic or CT criteria to define early pathologic stage.
A thickened mass or esophagus on posttreatment CT scan
or endoscopic ultrasonography does not appear able to dis-
tinguish fibrosis from residual or recurrent carcinoma.28,29
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In the future other modalities, such as positron-emission
tomography, may be able to help distinguish early-stage
patients who could undergo surgical salvage after failed
definitive chemoradiation therapy.
In conclusion, this study demonstrated increased mor-
bidity and hospital use after salvage esophagectomy per-
formed after failed definitive chemoradiation therapy
relative to planned esophagectomy performed 4 to 6 weeks
after preoperative chemoradiation therapy. Despite the
increased morbidity, mortality, and hospital use, a subset of
patients were cured after salvage esophagectomy, and long-
term survival appears to be associated with early pathologic
stage (T1 N0, T2 N0), R0 resection, and prolonged time to
relapse (>12 months). These data suggest that salvage
esophagectomy remains a therapeutic option for carefully
selected patients at experienced high-volume esophageal
referral centers.
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Discussion
Dr Douglas J. Mathisen (Boston, Mass). Congratulations to
you and your colleagues for bringing this subject to our attention.
This is a topic that we are likely to see more of in years to come,
so it is a worthwhile item to bring up at this meeting. I also com-
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mend you colleagues for having the courage to tackle these cases.
I think that those of us who have operated on patients who have
had failure of previous definitive chemoradiotherapy recognize
how difficult these cases are. These patients are difficult to operate
on, they are difficult to take care of after the operation, and, as we
have seen here, they present some challenges because of the com-
plications that can develop.
First, I think that we would probably both agree that it is diffi-
cult to come up with absolute conclusions on the basis of this
small experience, which translates into about a case per year. On
the other hand, I do think that you have brought to our attention a
number of important observations that we need to address. I think
that one of the most concerning aspects is the leak rate, and I won-
der whether you could share with us the technique that you have
used to do the anastomosis. I know that when faced with some of
these patients myself who have had either high-dose chemoradio-
therapy remotely or are receiving steroids, in addition to the tech-
nique that we have used, which I think is a sound one, I have
incorporated an intercostal muscle to reinforce the suture line,
which I certainly don’t do routinely but have done for these high-
risk patients.
Second, have you analyzed the CT scans of these patients to
look for clues that might discriminate patients who are going to be
at increased risk, such as patients who have pulmonary fibrosis,
mediastinal fibrosis, or a lot of thickening of the tissues that you
are likely to use for anastomosis?
Third, and importantly I think, if we are going to operate on
this group of patients, what about their quality of life after this
operation? I know that our experience in using high-dose
chemoradiotherapy with radiotherapy in the magnitude of 60 Gy
before the operation that some of these patients still have trouble
swallowing because of the effects of high doses of radiation. Have
you analyzed those survivors for their ability to swallow? Do they
need repeated dilations?
Finally, as you have looked at this experience are there certain
criteria that you have established in your own mind that might
allow you to exclude certain patients? In other words, you stated
that on restaging of these patients those with a low stage constitute
a favorable group. If they have T3 or T4 disease, they constitute an
unfavorable group. Do you have any thoughts about length of time
from radiation, the dose of radiation that was used, and the loca-
tion of the tumor?
Dr Swisher: Thank you, Dr Mathisen. The surgical technique
that was used most often was a single-layer hand-sewn anastomo-
sis in the neck and a stapled anastomosis in the chest. The high
leak rate that we observed has caused us concern and is probably
related to the high radiation level that had been delivered to the
esophagus and stomach. In some cases the patients had received
up to 90 Gy of radiation therapy. We have been looking at ways to
reduce the leak rate by using alternative vascularized conduits that
have not been in the radiation field. These alternative grafts can
include colon conduits, which can often be supercharged at the
neck, or long-segment interjejunal interpositions, which can be
microanastomosed at the neck. Both these conduits bring vascu-
larized grafts that have not been radiated to the operative field. It
is important to recognize, however, that only 1 of the 5 patients
who had a leak ultimately died of this complication. The most seri-
ous problems that we found in our patients were pulmonary prob-
lems, and I am uncertain whether these problems were due to the
high doses of radiation. Our radiation therapists are careful when
they deliver the radiation to ensure that the radiation fields spare
the lung. Unfortunately, most of these patients were initially
treated at outside hospitals, and the radiation fields may not have
been as carefully designed to avoid the lung. We have not been
able to pick out factors associated with a high risk of complica-
tions, but this may be due in part to the small sample size.
In terms of quality of life, the swallowing function was excel-
lent for the patients who survived long term. The 4 patients who
were alive and free of disease longer than 3 years did well and
swallowed without difficulty. However, the patients who did not
survive long term also did poorly. Their tumors recurred quickly,
and their quality of life was poor. I think that this gets to your next
point about whether we can select those patients that will do well.
Unfortunately, at present we do not have good criteria for selec-
tion. As noted in our presentation, those patients who had T3 or
greater pathologic class disease seldom survived more than 6
months. Current clinical staging techniques, such as endoscopic
ultrasonography or CT scan, are inadequate to pick out the patients
with early-stage disease, because many times one can see a mass
but is not able to determine whether this represents fibrosis or
viable tumor. At the time of the operation many of the patients
found on preoperative scans to have a large mass were found to
have only a small amount of viable tumor pathologically. So at
present we are limited in picking out early-stage disease before the
operation. In the future, perhaps positron-emission tomographic
activity will help assess the amounts of viable tumor in the pri-
mary and distant tumor sites.
Dr Raphael Bueno (Boston, Mass). I would like to congratu-
late you for presenting these data, because we see these patients
more frequently these days as patients seek further therapy. These
patients usually have recurrence after complete chemoradiation
therapy and tell us that their oncologists told them that they would
be cured, and here they are 15 months later with esophageal
obstruction. We find it difficult to tell during the operation whether
we are dealing with metastatic disease or just postradiation dam-
age. Have you used any particular techniques during the operation,
such as more frozen sections, to determine whether you are deal-
ing with fibrosis or penetrating T4 cancers?
Dr Swisher: At the time of operation we perform frozen sec-
tions of lymph nodes or suspected metastatic disease. If the lymph
nodes show viable tumor and are outside the resected field, then
we do not proceed with the operation. To date we have performed
resection on patients in whom the lymph nodes could be encom-
passed in the resection. In light of the current data, however, which
indicate no long-term survivors with involved lymph nodes, it
might be reasonable to be more selective when deciding whether
to proceed, especially if the condition could be palliated by other
means, such as stents.
Dr Thomas J. Kirby (Cleveland, Ohio). Could you comment
on your indications for surgery, in that you did not have any long-
term survivors with a tumor of T2 or greater? For example, if you
did preoperative endoscopic ultrasonography and found that the
patient had a T4 lesion, would you still consider that person a can-
didate for salvage esophagectomy?
Getting back to one of your other points, you said that your
high anastomotic leak rate may have been related to preoperative
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radiotherapy of the conduit. Half your lesions were in the upper
half of the esophagus, so I would doubt whether your conduit,
which I assume was the stomach, was included in the radiotherapy
field. Therefore one would have to conclude that the anastomotic
leak rate cannot be correlated to radiotherapy of the conduit.
Dr Swisher: It is important to realize that one can be fooled by
endoscopic ultrasonography, because a mass on endoscopic ultra-
sonography does not always represent viable tumor. We have had
patients with a large mass that was pathologically only T1 or T2.
Additionally, this experience was gained over a long period, so it
is only recently that we have had a chance to review it and see how
strikingly the long-term survival is related to the pathologic spec-
imen. This question gets to the problem again that it is very diffi-
cult at present to clinically stage these relapsed tumors. Perhaps in
the future positron-emission tomography or other noninvasive
staging modalities will improve the staging.
In terms of the fields of radiation that were delivered, they were
delivered at outside hospitals, so it was not possible to evaluate
them and correlate them with the leaks. A number of patients had
distal esophageal tumors, and we have not looked at whether the
leaks occurred primarily among those patients.
Dr Kirby. I would agree with your comments on endoscopic
ultrasonography, but it would still provide the surgeon with addi-
tional information regarding operability. I have just one follow-up
question. If you do not trust the results of endoscopic ultrasonog-
raphy, do you think that there is a role for thoracoscopy? If you
took a biopsy from a lymph node thoracoscopically and found it to
represent N1 or N2 disease, would you still consider that patient a
candidate for an esophagectomy, because you did not have any
long-term survivors in that group of patients?
Dr Swisher. That is a good point, and thoracoscopy may be
valuable in that situation. Again, we have to be cautious because
the risks of thoracoscopy and laparoscopy may also be higher for
these patients. It is important to realize that this is a small study
with only 13 cases acquired over a long period. We really need to
have a prospective study in which we can carefully evaluate these
patients in a controlled fashion to pick out which factors are
important.
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